Pooling signaling and costimulatory domains in flexible car design
AssigneeCelyad S.A.
InventorsDavid GILHAM, Jennifer BOLSÉE, Lorraine SPRINGUEL
Life of this patent
Estimating the term…
Loading patent…
AssigneeCelyad S.A.
InventorsDavid GILHAM, Jennifer BOLSÉE, Lorraine SPRINGUEL
Estimating the term…
The present application relates to the field of immunotherapy, more particularly to the field of chimeric antigen receptors (CARs). Currently, second and third generation CAR designs are quite rigid in that they combine fixed costimulatory domains in cis on the same intracellular protein domain. Trans signaling is not equivalent as costimulatory receptors have different expression levels or stoichiometry. Here, a ‘mix and match’ approach is proposed where different signaling and costimulatory domains are present on separate chains within the same CAR complex, allowing increased flexibility and control of the nature and strength of the CAR-generated signal. Also proposed are polynucleotides, vectors encoding the transmembrane polypeptide chains and cells expressing such CARs. These cells are particularly suitable for use in immunotherapy, and strategies to treat diseases such as cancer using these cells are also provided.
A combination of at least two isolated nucleic acid molecules, wherein
The combination of claim 2, wherein the signaling domain is selected from the group consisting of a CD3 zeta chain, a Fc epsilon RI gamma chain and a CD3 epsilon chain.
A nucleic acid molecule encoding a chimeric antigen receptor, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a signaling domain or costimulatory domain;
Dependencies are inferred from the claim text.